CytoDyn Inc's Nader Pourhassan tells Proactive that Brazil’s regulatory authority Agência Nacional de Vigilância Sanitária (ANVISA) has approved the start of an additional Phase 3 CD16 clinical trial of its flagship drug leronlimab to treat critically ill coronavirus patients. Pourhassan says the new clinical trial will focus on hospitalized COVID-19 patients in critical condition who require mechanical and invasive ventilation or Extracorporeal Membrane Oxygenation (ECMO).